Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Transcription

1 Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division of Infectious Diseases, UCSF Objectives Establish importance of testing and treatment for latent tuberculosis infection infection (LTBI) Discuss patient populations to be tested Review tests currently available Explore treatment options Discuss diagnosis of active TB PART 1: WHY TEST? 3 4 1

2 Natural History of TB Active vs. Latent Tuberculosis Exposure to infectious TB Not infected 5% Develop primary Latent TB infection (LTBI) 90% Remain latently infected 5% Progression to Reactivation Active TB disease Cough, fever, weight loss, night sweats, hemoptysis Contagious TB cases Latent TB infection No symptoms Not contagious May progress to 10% lifetime risk 10% annual risk among HIV infected Not TB cases 5 6 TB Cases in the United States Reported TB in California, ,000 25,000 20,000 15,000 10,000 5,000 0 First increase in 23 yrs Foreign born 81% US born 19% CDC, Annual Report, 2015 Salinas, et al. MMWR, Each = 1 TB case (Total = 2137) 8 2

3 Consequences of Active TB If TB disease is curable, why is prevention so important? 1. Mortality ~ 10% of patients with TB do not survive Pascopella, Open Forum Infect Dis, Morbidity After treatment, patients have shorter life expectancy Hoger, Int J Tuberc Lung Dis, 2014; Shuldiner, Int J Tuberc Lung Dis, Cost of treating Hospitalization and outpatient case management Balaban, Public Health Rep, Public Health Treatment of latent TB infection reduces future TB transmission 9 >2100 cases per yr How do TB Cases Occur in California? or Why test for latent TB infection? Recent Transmission* Importation 0% 20% 40% 60% 80% 100% * France et al, Am J Epidemiol Reactivation 10 ~10,000 cases of Burden of TB in the U.S. 2.4 Million Estimated TB Infections, California 2014 U.S. Born Foreign Born ~15 million with latent TB infection 0.55 Million 1.85 Million CDC, Annual Report, 2015 Miramontes, PLOS One, 2015 American Community Survey, % 20% 40% 60% 80% 100% Estimated by applying nativity and race/ethnicity specific TB infection prevalence from NHANES (Miramontes, 2015) to the California ACS population estimates using TST for US born and IGRA for foreign 12 born 3

4 Millions of persons Latent TB Infection: Number, awareness, and treatment California, M U.S. born Foreign born Barriers to Treatment of Latent TB Infection Nonspecific guidelines Confusion about which groups should (or should not) be tested and treated Limited resources in busy clinical settings Suboptimal tests and treatment options Not considered an important clinical problem % 12% LTBI prevalence Aware of LTBI Treated for LTBI Estimated using National Health and Nutrition Examination Survey, applied to the California population Part 1: Key Points Most TB cases in the U.S. are due to reactivation and are therefore preventable TB disease remains a substantial contributor to morbidity and mortality Historical barriers have impeded adoption in many practice settings PART 2: WHO TO TEST?

5 Why not test everyone? Natural History of TB Testing populations with low prevalence will result in many false positive results Example: Among low risk U.S. born patients: Risk for infection Exposure to infectious TB Latent TB infection (LTBI) 90% Remain latently infected Prevalence of latent TB infection False positive rate 2.8% 46% Develop primary Risk for progression 5% Progression to Reactivation Miramontes, PLOS One, 2015 Pai, Clin Micro Rev, Who to Test for LTBI? Risk of Exposure (e.g., Foreign born) Risk of Progression (e.g., diabetes) TB Risk Factors Exposure/Infection Progression Foreign born* HIV/AIDS Known contact to infectious case Transplant Homeless Silicosis Corrections Cancer (head/neck) IV drug abuse ESRD on dialysis Long term care facilities Steroids Healthcare workers TNF alpha blockers Diabetes mellitus Underweight Smoking Recent infection 19 *From a country with elevated TB rate CDC, MMWR,

6 Risk Assessment For use by primary care providers Simplicity, clarity over detail A decision to test is a decision to treat Companion Fact Sheet 22 Prioritize if necessary If health system resources do not allow for testing all foreign born persons: Prioritize medical risk for progression 1. Diabetes mellitus 2. Smoker within past 1 year 3. End stage renal disease 4. leukemia or lymphoma 5. Silicosis 6. cancer of head or neck 7. intestinal bypass/gastrectomy 8. chronic malabsorption 9. body mass index California Department of Public Health,

7 US Preventive Services Task Force Population Adults who are at increased risk for tuberculosis: persons born in, or former residents of, countries with increased tuberculosis prevalence persons who live in, or have lived in, high risk congregate settings (such as homeless shelters and correctional facilities) Recommendation Grade The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations that are at increased risk. What about age? Younger persons have longer expected life during which TB progression could occur 25 30% of TB cases in 65+ age group LTBI prevalence increases with age Older age is a risk factor for death if active TB develops No upper limit of age has been set for TB screening recommendation statement144/latent 2tuberculosis infection screening CDC Annual Report, 2015 Miramontes, PLOS One, 2015 Pascopella OFID Years in US at TB Diagnosis California, Years in US at TB Diagnosis California, TB Cases % in US > 5.9 years 50% in US >16 years TB Cases TB rate per 100,000 Years in US 27 Years in US 28 7

8 What about high risk congregate settings? Homeless shelters, corrections Risk and epidemiology can vary Geography, type of facility Regulatory and legal mandates may apply Screening programs integrated into sites Shelter screening programs, corrections screening, occupational health Check with your local public health TB control program Part 2: Key Points Patients should have a TB risk assessment Foreign birth, immunosuppressed, contact A decision to test is a decision to treat Age and years since U.S. entry are not contraindications to testing or treatment Natural History of TB Test 90% Remain latently infected Exposure to infectious TB Latent TB infection (LTBI) PART 3: HOW TO TEST? 5% Develop primary 5% Progression to Reactivation

9 Tuberculin Skin Test (TST) aka PPD Tuberculin Skin Test (TST) Delayed type hypersensitivity reaction How to read: Measure induration (not erythema) at hrs Record millimeters Positive test: 5mm for immunosuppressed including HIV, recent contacts, fibrotic CXR 10mm for all others with TB risk Interferon Gamma Release Assays (IGRAs) QuantiFERON TB Gold (QFT) Reported as positive, negative, or indeterminate T SPOT.TB (T Spot) Reported as positive, borderline, negative, or indeterminate IGRA vs. TST Advantages over TST Not affected by BCG vaccination Not affected by most non tuberculous mycobacteria Interpretation is more objective No return visit needed for interpretation of test Patients and providers may lack confidence in TST results 35 CDC, MMWR, 2010 Pai, Clin Micro Rev,

10 TST and QFT Specificity Specificity 95% confidence interval TST without BCG TST with BCG QFT Testing Foreign Born Patients Using a test with poor specificity will result in many false positive results Example: Among foreign born patients (prevalence 16%): Test False positive rate QFT 12% TST 73% Menzies, Ann Intern Med, 2007 Pai, Ann Intern Med, Pai, Clin Micro Rev, 2014 Miramontes, PLOS One, Diagnosing Latent TB Infection TSTs and IGRAs cannot distinguish between latent TB infection and Latent TB infection?? Positive TST or IGRA Active TB disease must be evaluated Symptom screen + chest radiograph Possible sputum collection: 1. AFB smear and culture 2. TB PCR/NAAT Active TB disease RULE OUT ACTIVE DISEASE BEFORE STARTING LTBI TREATMENT!! Get chest radiograph If abnormal collect sputum If sputum collected: Either start empiric treatment for active disease Or await final culture results before starting LTBI Rx

11 Part 3: Key Points Either IGRA or TST can aid in the diagnosis of latent TB infection Neither test can distinguish between latent TB infection and IGRAs have advantages over TST in certain situations PART 4: HOW TO TREAT? Exposure to infectious TB Natural History of TB 5% Develop primary TST or IGRA Latent TB infection (LTBI) Treatment of LTBI 90% Remain latently infected X 5% Progression to Reactivation Treatment Regimens for Latent TB Infection Medication(s) Frequency Duration Doses Isonizaid (INH) Daily 6 9 months Rifampin Daily 4 months 120 Rifapentine + INH Weekly 3 months

12 Isoniazid (INH) Advantages Gold standard of treatment for latent TB infection Efficacy is 60% 90%, depending on duration of treatment Fewer drug drug interactions Disadvantages Adherence Initiation and completion rates <50% Hepatotoxicity Incidence 0.1%, but increases with age Clinic time required for 9 monthly visits Pl H6 R3 Placebo 6 months INH 3 month Rifampin Nolan, JAMA, 1999 Smieja, Cochrane Database Syst Rev, 2000 Menzies, Ann Int Med, Hong Kong Chest Service/Tuberculosis Research Centre, Am Rev Respir Dis, 1992 Rifampin Advantages: Less hepatotoxicity (~5x less than INH) Greater adherence (78% RIF vs. 60% INH) Disadvantages: Less evidence of efficacy Could be 17% less efficacious than INH and still be cost saving Multiple drug interactions Warfarin, oral contraceptives, methadone, protease inhibitors INH RPT INH No. of patients 3,986 3,745 Frequency Weekly Daily Duration 3 months 9 months Administration Directly observed Self administered Hong Kong Chest Service/Tuberculosis Research Centre, Am Rev Respir Dis, 1992 Villarino, Am J Respir Crit Care Med, 1997 Menzies, Ann Intern Med, 2008 Holland, Am J Respir Crit Care 47 Sterling, NEJM, 2011 Med,

13 Prevent TB Study Results INH RPT INH P value Effectiveness 1.9 per 1, per 1,000 Non inferior Completion 82.1% 69.0% P<0.001 Hepatotoxicity 0.4% 2.7% P<0.001 Further Studies of INH RPT Children ( 2 yrs) Non inferior to 9 months of INH Self administered therapy (SAT) Completion rates: SAT 78% vs. DOT 85% (noninferior) HIV Non inferior to 9 months of INH Unable to receive ART in first 90 days Sterling, NEJM, Villarino, JAMA Pediatrics, 2015 Belknap, CROI, 2015 Sterling, CROI, INH RPT Advantages: Less hepatotoxicity (~ 7x less than INH) Greater adherence (82% INH RPT vs. 69% INH) Disadvantages: Multiple drug interactions Pill burden Flu like syndrome (2.2%) Bliven Sizemore, Int J Tuberc Lung Dis, 2015 Sterling, Clin Infect Dis, Preventing Hepatotoxicity Patient counseling Avoid alcohol and acetominophen Stop if symptoms develop: nausea, anorexia, abdominal pain, jaundice, rash Monitoring Monthly review for symptoms of adverse reactions (1 month supply) Monitor with baseline and periodic LFTs if: Chronic ETOH, viral hepatitis, known liver disease, HIV, pregnant/3 months post partum, other hepatotoxic medications,? > 35 yo Saukkonen Am J Resp Crit Care Med

14 Part 4: Key Points INH is the traditional gold standard, but has extremely low treatment initiation and completion rates Short course regimens have higher completion rates and are less hepatotoxic PART 5: DIAGNOSING ACTIVE TB INH RPT (3 months) is as efficacious as INH (9 months) Clinical Presentation: Signs and Symptoms Cough (dry/productive sputum) 75 80% Weight loss 45 75% Fatigue 60 70% Fever 50 60% Night sweats 50 55% Hemoptysis 25 35% Pleuritic chest pain No symptoms 10 20% Radiographic Patterns of Pulmonary TB Pattern Infiltrate Typical (Reactivation) 85% upper Cavitation Common (20%) Rare in children and primary TB Adenopathy Uncommon More common in children and primary TB Barnes 1988, Miller Effusion May be present 56 14

15 57 4/14/2016 Sputum AFB smear Smear positive 10 4 bacilli per ml Smear AFB amount correlates with infectiousness 40 60% of culture positive cases will be smear negative Three smear negative specimens does not rule out TB! What is the added value of NAAT? For AFB smear ( ): 50 70% of smear /culture + cases will be + by NAAT start treatment (earlier) If NAAT ( ), the likelihood of TB lower Release from isolation earlier (2 Xpert results finds all smear +) Still start treatment if suspicion is high For AFB smear (+): NAAT can confirm TB quickly If NAAT negative, prevent falsely diagnosing TB (likely NTM if inhibitors are ruled out and result repeated) Luetkemeyer Clin Infect Dis Xpert MTB/RIF Test Performance Compared with Culture, U.S. patients Use of NAATs! Smear (+) 96.7% (59/61) Smear ( ) 59.3% (16/27) Sensitivity 1 Xpert 2 Xperts 100% (62/62) 71.4% (20/28) Specificity 99.2% NAAT should be used unless results would not impact clinical or public health management Xpert results showing Rif resistance should: Be confirmed using sequencing and/or culture Trigger suspicion for MDR TB (not Rif monor) Luetkemeyer Clin Infect Dis CDC MMWR October 18, 2013 / 62(41);

16 Summary: Why test? Most TB cases in the U.S. are preventable TB disease still causes substantial morbidity and mortality SUMMARY 15 million persons in the U.S. are infected with TB Summary: Who to test? Patients should have a TB risk assessment Foreign birth, immunosuppressed, contact A decision to test is a decision to treat Age and years since U.S. entry are not contraindications to testing or treatment Summary: How to test? Both IGRAs or TSTs can be used to support the diagnosis of latent TB infection Neither test can distinguish between latent TB infection and IGRAs have advantages over TST in certain situations

17 Summary: How to treat? INH has extremely low treatment initiation and completion rates Short course regimens have higher completion rates and are less hepatotoxic INH RPT (3 months) is as efficacious as INH (9 months) Conclusions Testing and treatment of latent TB infection is crucial to accelerating the decline of TB in the United States New tools can help simplify and improve management of latent TB infection: 1. Simple TB risk assessment 2. IGRAs 3. Short course regimens Acknowledgments Brian Baker Caitlin Reed Local TB Control Programs Jenny Flood Lisa Pascopella Peter Oh Janice Westenhouse Neha Shah Gisela Schecter Use the California TB Risk Assessment 67 References and Resources California DPH TB Control Branch: Risk Assessment: CA TB Risk Assessment and Fact Sheet.pdf INH+Rifapentine Fact Sheet: INH RIF LTBI fact sheet.pdf CDC IGRA Guideline: INH+Rifapentine Guideline: NAAT Guideline: Xpert MMWR: California TB Controllers Association IGRA Guideline: TST in 3D: Curry International Tuberculosis Center (Warmline Consultation Service) or